Prothena Corporation plc(PRTA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PRTA Prothena Corporation plc

交易中 06-08 12:20:55 EDT

8.72

-0.07

-0.80%

最高8.89	最低8.66	成交量9.17万
今开8.80	昨收8.79	日振幅2.62%
总市值4.57亿	流通市值3.33亿	总股本5,235万
成交额80.21万	换手率0.24%	流通股本3,817万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PRTA","market":"US","secType":"STK","nameCN":"Prothena Corporation plc","latestPrice":8.72,"timestamp":1780935654851,"preClose":8.79,"halted":0,"volume":91739,"delay":0,"changeRate":-0.007963594994311549,"floatShares":38170600,"shares":52353237,"eps":-2.813057,"marketStatus":"交易中","change":-0.07,"latestTime":"06-08 12:20:55 EDT","open":8.8,"high":8.89,"low":8.66,"amount":802143.248206,"amplitude":0.026166,"askPrice":8.73,"askSize":151,"bidPrice":8.71,"bidSize":473,"shortable":3,"etf":0,"ttmEps":-2.813057,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1780948800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1355806800000,"exchange":"NASDAQ","adjPreClose":8.79,"preHourTrading":{"tag":"盘前","latestPrice":9,"preClose":8.79,"latestTime":"08:27 EDT","volume":2,"amount":17.720002,"timestamp":1780921633977,"change":0.21,"changeRate":0.023891,"amplitude":0.031854},"postHourTrading":{"tag":"盘后","latestPrice":8.79,"preClose":8.79,"latestTime":"16:54 EDT","volume":7581,"amount":66636.48,"timestamp":1780692883404,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.394596,"impliedVol":0.5976,"impliedVolPercentile":0.4701},"requestUrl":"/m/hq/s/PRTA","defaultTab":"news","newsList":[{"id":"1157441467","title":"Prothena Corporation plc更新2026财年经营与投资活动净现金使用额至1800-2300万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157441467","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157441467?lang=zh_cn&edition=full","pubTime":"2026-05-08 04:30","pubTimestamp":1778185837,"startTime":"0","endTime":"0","summary":"生物科技公司Prothena Corporation plc近日宣布，对2026财年经营活动和投资活动产生的净现金使用额预期作出调整。根据最新预测，该公司预计全年净现金使用额将介于1800万至2300万美元区间。\n此次更新反映了公司对研发管线推进及运营资金管理的动态评估。作为专注于神经退行性疾病创新疗法的企业，Prothena将持续优化资源分配以支持核心项目的临床开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181539925","title":"Prothena公司Coramitug三期Cleopattra试验完成约1280名受试者入组 主要研究终点预计2029年达成","url":"https://stock-news.laohu8.com/highlight/detail?id=1181539925","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181539925?lang=zh_cn&edition=full","pubTime":"2026-04-28 04:06","pubTimestamp":1777320394,"startTime":"0","endTime":"0","summary":"生物制药公司Prothena Corporation plc宣布，其靶向淀粉样蛋白抗体Coramitug的三期临床试验CLEOPATRA已完成约1280名早期阿尔茨海默病患者的入组工作。该全球多中心研究旨在评估药物对患者认知功能的改善效果，主要研究终点数据预计将于2029年获得。此次里程碑式的患者招募完成，为后续临床数据解读奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127664491","title":"Prothena宣布诺和诺德获得美国FDA对Coramitug (Prx004)治疗转甲状腺素蛋白淀粉样变性心肌病的快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1127664491","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127664491?lang=zh_cn&edition=full","pubTime":"2026-04-28 04:06","pubTimestamp":1777320382,"startTime":"0","endTime":"0","summary":"Prothena Corporation plc今日宣布，其合作伙伴诺和诺德公司已成功获得美国食品药品监督管理局授予的快速通道资格认定，该认定针对其在研药物Coramitug用于治疗伴有心肌病的转甲状腺素蛋白淀粉样变性。此项重要的监管里程碑将有望加速Coramitug的临床开发与审评进程，为罹患此种严重疾病的患者带来新的治疗希望。Coramitug作为一种在研的单克隆抗体，其设计目标是选择性清除这些致病蛋白沉积。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165981316","title":"诺和诺德与Prothena合作的Coramitug三期ATTR-CM试验预计2029年完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1165981316","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165981316?lang=zh_cn&edition=full","pubTime":"2026-03-10 04:06","pubTimestamp":1773086777,"startTime":"0","endTime":"0","summary":"诺和诺德公司针对转甲状腺素蛋白淀粉样变性心肌病开展的Coramitug三期临床试验，预计将于2029年完成最终研究。该试验是诺和诺德与生物技术公司Prothena Corporation plc合作推进的重要项目，旨在评估候选药物对ATTR-CM患者的疗效与安全性。ATTR-CM作为一种进行性、致命性的罕见疾病，目前治疗选择有限。Coramitug作为一款备受关注的在研疗法，其三期临床试验的推进将为该疾病领域带来新的希望。随着试验的逐步推进，后续数据披露将成为行业关注焦点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165076358","title":"Prothena公司宣布从诺和诺德获得与Coramitug（前称Prx004）治疗ATTR淀粉样变性心肌病持续三期临床试验相关的5000万美元临床里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1165076358","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165076358?lang=zh_cn&edition=full","pubTime":"2026-03-10 04:06","pubTimestamp":1773086773,"startTime":"0","endTime":"0","summary":"Prothena公司宣布，其合作伙伴诺和诺德已向公司支付5000万美元的临床里程碑款项。该笔款项的触发与Coramitug（曾用代号Prx004）用于治疗转甲状腺素蛋白淀粉样变性心肌病的三期临床试验进展相关。目前，该项关键性临床试验正在持续推进中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616286345","title":"Prothena Corporation Plc盘中异动 早盘股价大涨6.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616286345","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616286345?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:30","pubTimestamp":1772461829,"startTime":"0","endTime":"0","summary":"北京时间2026年03月02日22时30分，Prothena Corporation Plc股票出现波动，股价大幅上涨6.34%。截至发稿，该股报9.22美元/股，成交量2.6827万股，换手率0.05%，振幅0.00%。Prothena Corporation Plc股票所在的生物技术行业中，整体涨幅为0.00%。Prothena Corporation Plc公司简介：Prothena Corp PLC是一家临床生物技术公司，专注于蛋白质失调和具有改变破坏性神经退行性疾病以及罕见和周围淀粉样蛋白疾病进程潜力的研究性治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030222302997a7ae23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030222302997a7ae23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AL","PRTA","IE00B19Z6F94.USD","BK4572","IE0034390439.USD","LU1169589451.USD","BK4104","LU1169590202.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162541061","title":"Prothena Corporation plc：有望在2026年底前累计获得高达1.05亿美元临床里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1162541061","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162541061?lang=zh_cn&edition=full","pubTime":"2026-02-20 05:10","pubTimestamp":1771535411,"startTime":"0","endTime":"0","summary":"Prothena Corporation plc宣布，公司具备在2026年底前累计获得高达1.05亿美元临床里程碑付款的潜力。这一预期收益将基于其研发管线中关键项目的临床进展达成情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603578527","title":"Prothena Corporation Plc盘中异动 早盘急速下挫5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603578527","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603578527?lang=zh_cn&edition=full","pubTime":"2026-01-12 23:31","pubTimestamp":1768231908,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日23时31分，Prothena Corporation Plc股票出现波动，股价大幅下挫5.00%。截至发稿，该股报8.73美元/股，成交量8.1218万股，换手率0.15%，振幅4.46%。Prothena Corporation Plc股票所在的生物技术行业中，整体跌幅为1.42%。Prothena Corporation Plc公司简介：Prothena Corp PLC是一家临床生物技术公司，专注于蛋白质失调和具有改变破坏性神经退行性疾病以及罕见和周围淀粉样蛋白疾病进程潜力的研究性治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112233149953c70b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112233149953c70b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PRTA","LU1169590202.USD","IE00B19Z6F94.USD","BK4104","BK4139","LU1169589451.USD","BK4572","AL","IE0034390439.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2600801503","title":"Prothena Corporation Plc盘中异动 股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600801503","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600801503?lang=zh_cn&edition=full","pubTime":"2026-01-03 04:01","pubTimestamp":1767384077,"startTime":"0","endTime":"0","summary":"北京时间2026年01月03日04时01分，Prothena Corporation Plc股票出现波动，股价快速跳水5.03%。截至发稿，该股报9.07美元/股，成交量31.6116万股，换手率0.59%，振幅6.28%。Prothena Corporation Plc股票所在的生物技术行业中，整体跌幅为0.08%。Prothena Corporation Plc公司简介：Prothena Corp PLC是一家临床生物技术公司，专注于蛋白质失调和具有改变破坏性神经退行性疾病以及罕见和周围淀粉样蛋白疾病进程潜力的研究性治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103040117a4957efc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103040117a4957efc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1169589451.USD","IE00B19Z6F94.USD","AL","BK4104","PRTA","IE0034390439.USD","LU1169590202.USD","BK4139","BK4572"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518760612","title":"Prothena Corporation Plc盘中异动 大幅跳水5.13%报14.49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518760612","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518760612?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:45","pubTimestamp":1741617927,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时45分，Prothena Corporation Plc股票出现波动，股价急速下挫5.13%。截至发稿，该股报14.49美元/股，成交量6.7649万股，换手率0.13%，振幅4.13%。Prothena Corporation Plc股票所在的生物技术行业中，整体跌幅为0.06%。Prothena Corporation Plc公司简介：Prothena Corp PLC 是一家生物技术公司，专注于蛋白质失调和实验性治疗的管道，有可能改变破坏性罕见的神经退行性疾病和外周淀粉样变性疾病的进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310224527a26a411d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310224527a26a411d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0034390439.USD","IE00B19Z6F94.USD","BK4104","AL","BK4139","PRTA","BK4572"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517098565","title":"Prothena Corporation Plc盘中异动 下午盘快速拉升5.16%报15.07美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517098565","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517098565?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:01","pubTimestamp":1741118514,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时01分，Prothena Corporation Plc股票出现波动，股价急速拉升5.16%。截至发稿，该股报15.07美元/股，成交量31.3781万股，换手率0.58%，振幅7.82%。Prothena Corporation Plc股票所在的生物技术行业中，整体涨幅为0.11%。Prothena Corporation Plc公司简介：Prothena Corp PLC 是一家生物技术公司，专注于蛋白质失调和实验性治疗的管道，有可能改变破坏性罕见的神经退行性疾病和外周淀粉样变性疾病的进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030504015496399197&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030504015496399197&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4572","IE0034390439.USD","BK4104","PRTA","AL","IE00B19Z6F94.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516165803","title":"Prothena Corporation Plc盘中异动 快速跳水5.00%报15.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516165803","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516165803?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:53","pubTimestamp":1741017189,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时53分，Prothena Corporation Plc股票出现波动，股价快速下跌5.00%。截至发稿，该股报15.02美元/股，成交量9.8825万股，换手率0.18%，振幅6.44%。Prothena Corporation Plc股票所在的生物技术行业中，整体跌幅为0.38%。Prothena Corporation Plc公司简介：Prothena Corp PLC 是一家生物技术公司，专注于蛋白质失调和实验性治疗的管道，有可能改变破坏性罕见的神经退行性疾病和外周淀粉样变性疾病的进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032353109637c0fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032353109637c0fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B19Z6F94.USD","BK4572","BK4104","AL","IE0034390439.USD","PRTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516379704","title":"Prothena Corporation Plc盘中异动 股价大涨5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379704","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516379704?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:05","pubTimestamp":1740758736,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日00时05分，Prothena Corporation Plc股票出现异动，股价大幅上涨5.35%。截至发稿，该股报15.94美元/股，成交量11.705万股，换手率0.22%，振幅4.73%。Prothena Corporation Plc股票所在的生物技术行业中，整体涨幅为0.14%。Prothena Corporation Plc公司简介：Prothena Corp PLC 是一家生物技术公司，专注于蛋白质失调和实验性治疗的管道，有可能改变破坏性罕见的神经退行性疾病和外周淀粉样变性疾病的进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030100053696342e40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030100053696342e40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AL","IE0034390439.USD","BK4572","IE00B19Z6F94.USD","BK4104","PRTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513720671","title":"Prothena Corporation Plc盘中异动 股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513720671","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513720671?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:57","pubTimestamp":1740409029,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时57分，Prothena Corporation Plc股票出现异动，股价快速下挫5.08%。截至发稿，该股报14.77美元/股，成交量4.0264万股，换手率0.07%，振幅6.52%。Prothena Corporation Plc股票所在的生物技术行业中，整体涨幅为0.22%。Prothena Corporation Plc公司简介：Prothena Corp PLC 是一家生物技术公司，专注于蛋白质失调和实验性治疗的管道，有可能改变破坏性罕见的神经退行性疾病和外周淀粉样变性疾病的进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225709962e9f4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225709962e9f4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AL","BK4572","IE00B19Z6F94.USD","PRTA","IE0034390439.USD","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513759832","title":"Prothena Corporation Plc2024财年实现净利润-1.22亿美元，同比增加17.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513759832","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513759832?lang=zh_cn&edition=full","pubTime":"2025-02-24 00:01","pubTimestamp":1740326488,"startTime":"0","endTime":"0","summary":"2月24日，Prothena Corporation Plc公布财报，公告显示公司2024财年净利润为-1.22亿美元，同比增加17.01%；其中营业收入为1.35亿美元，同比增加47.75%，每股基本收益为-2.27美元。从资产负债表来看，Prothena Corporation Plc总负债60.18百万美元，其中短期债务2.61百万美元，资产负债比为0.10，流动比率为0.10。机构评级：截至2025年2月24日，当前有8家机构对Prothena Corporation Plc目标价做出预测，其中目标均价为49.75美元，其中最低目标价为20.00美元，最高目标价为94.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000219abd9c80c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000219abd9c80c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PRTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513397218","title":"坎托菲茨杰拉德公司：重申Prothena Corp(PRTA.US)评级，由增持调整至增持评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513397218","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513397218?lang=zh_cn&edition=full","pubTime":"2025-02-22 01:11","pubTimestamp":1740157919,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：重申Prothena Corp(PRTA.US)评级，由增持调整至增持评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/22011148321022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PRTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513292229","title":"Citizens Capital Markets：重申Prothena Corp(PRTA.US)评级，由优于大市调整至优于大市评级, 目标价由80.00美元调整至80.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513292229","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513292229?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:05","pubTimestamp":1740153913,"startTime":"0","endTime":"0","summary":"Citizens Capital Markets：重申Prothena Corp(PRTA.US)评级，由优于大市调整至优于大市评级, 目标价由80.00美元调整至80.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/22000548320824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PRTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146597478","title":"异动解读 | Prothena公司新药研发进展顺利,股价盘中大涨7.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146597478","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146597478?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:50","pubTimestamp":1740149453,"startTime":"0","endTime":"0","summary":"生物技术公司Prothena Corporation plc(PRTA)今日盘中股价大涨7.28%,引发市场高度关注。\n\n据报道,该公司新药研发工作取得了重大进展,其针对淀粉样蛋白轻链淀粉样变性(AL)、帕金森病等疾病的候选药物进展顺利,市场预期公司长期增长前景看涨。\n\nProthena公司主攻蛋白质失调和实验性疗法,在罕见神经退行性疾病和外周淀粉样变性疾病等领域具有独特的产品线。投资者对公司的创新能力和治疗前景越来越乐观,推动了今日该股大涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Prothena公司新药研发进展顺利,股价盘中大涨7.28%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PRTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513966062","title":"Prothena Corporation Plc盘中异动 早盘快速上涨7.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513966062","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513966062?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:32","pubTimestamp":1740148325,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时32分，Prothena Corporation Plc股票出现异动，股价快速上涨7.67%。截至发稿，该股报16.42美元/股，成交量2.6111万股，换手率0.05%，振幅7.61%。Prothena Corporation Plc股票所在的生物技术行业中，整体涨幅为0.43%。Prothena Corporation Plc公司简介：Prothena Corp PLC 是一家生物技术公司，专注于蛋白质失调和实验性治疗的管道，有可能改变破坏性罕见的神经退行性疾病和外周淀粉样变性疾病的进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223205988dde38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223205988dde38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AL","BK4104","IE00B19Z6F94.USD","IE0034390439.USD","BK4572","PRTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192729731","title":"Prothena公司2024年第四季度GAAP每股收益$(1.08)不及预期$(1.04)，销售额$2.12百万不及预期$7.53百万","url":"https://stock-news.laohu8.com/highlight/detail?id=1192729731","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192729731?lang=zh_cn&edition=full","pubTime":"2025-02-21 05:14","pubTimestamp":1740086089,"startTime":"0","endTime":"0","summary":"Prothena公司报告季度每股亏损$，未能达到分析师一致预期的$，差异为3.85%。相比去年同期的销售额$31.6万，这是一个571.84%的增长。以上内容来自Benzinga Earnings专栏，原文如下：Prothena Corp  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 3.85 percent. This is a 14.29 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $2.12 million which missed the analyst consensus estimate of $7.53 million by 71.82 percent.  This is a 571.84 percent increase over sales ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Prothena公司2024年第四季度GAAP每股收益$(1.08)不及预期$(1.04)，销售额$2.12百万不及预期$7.53百万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRTA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.prothena.com","stockEarnings":[{"period":"1week","weight":-0.1365},{"period":"1month","weight":-0.2138},{"period":"3month","weight":-0.0834},{"period":"6month","weight":-0.206},{"period":"1year","weight":0.7372},{"period":"ytd","weight":-0.0796}],"compareEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.2437},{"period":"ytd","weight":0.0816}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Prothena Corporation plc于2012年9月26日根据爱尔兰法律成立，并于2012年10月25日重新注册为爱尔兰公共有限公司。该公司是一家晚期临床生物技术公司，拥有蛋白质失调方面的专业知识和一系列研究疗法，有可能改变破坏性神经退行性疾病和罕见的周围淀粉样蛋白疾病的病程。该公司全资拥有的项目包括用于潜在治疗AL淀粉样变性的birtamimab，以及用于潜在治疗阿尔茨海默病的一系列项目，包括针对β-淀粉样蛋白（A β）的PRX012和新型A β-tau双联疫苗PRX123。","yearOnYearQuotes":[{"month":1,"riseRate":0.357143,"avgChangeRate":-0.074184},{"month":2,"riseRate":0.571429,"avgChangeRate":0.090148},{"month":3,"riseRate":0.642857,"avgChangeRate":0.048493},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.103349},{"month":5,"riseRate":0.5,"avgChangeRate":0.01008},{"month":6,"riseRate":0.642857,"avgChangeRate":0.118554},{"month":7,"riseRate":0.769231,"avgChangeRate":0.11888},{"month":8,"riseRate":0.461538,"avgChangeRate":0.028746},{"month":9,"riseRate":0.461538,"avgChangeRate":0.053626},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.009835},{"month":11,"riseRate":0.538462,"avgChangeRate":0.066895},{"month":12,"riseRate":0.230769,"avgChangeRate":-0.049099}],"exchange":"NASDAQ","name":"Prothena Corporation plc","nameEN":"Prothena Corp PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Prothena Corporation plc(PRTA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Prothena Corporation plc(PRTA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Prothena Corporation plc,PRTA,Prothena Corporation plc股票,Prothena Corporation plc股票老虎,Prothena Corporation plc股票老虎国际,Prothena Corporation plc行情,Prothena Corporation plc股票行情,Prothena Corporation plc股价,Prothena Corporation plc股市,Prothena Corporation plc股票价格,Prothena Corporation plc股票交易,Prothena Corporation plc股票购买,Prothena Corporation plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Prothena Corporation plc(PRTA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Prothena Corporation plc(PRTA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}